Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPHA-ORBIT phase 3 study of navenibart for prophylaxis of hereditary angioedema
MOH_2025-08-10_014229Phase 3Not yet recruiting
- Sponsor
- Astria Therapeutics
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of navenibart in hereditary angioedema (HAE) (3 arms), sponsored by Astria Therapeutics. Primary endpoint: Efficacy in prevention of hereditary angioedema attacks. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on MOH_2025-08-10_014229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-08-10_014229.